New study for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Trial ID:
IRB-25-8601
Marin Xavier, MD

Inclusion Criteria

Patients must:

  • Be 18 years or older.
    Have confirmed CLL or SLL diagnosis.
    Have received 1 or more prior therapies for CLL/SLL, and at least 2 cycles of each therapy.
    Have an ECOG status of 0, 1, or 2.
    Have adequate laboratory tests.
    Have adequate liver and renal functions.

Exclusion Criteria

Patients must not:

  • Have known active prolymphocytic leukemia or currently suspected Richter's transformation.
    Have active symptomatic COVID-19 infection.
    Have known central nervous system involvement by CLL/SLL.
    Have prior autologous stem cell transplant < 3 months after transplant; or prior CAR-T therapy < 3 months after cell infusion.
    Have prior allogeneic stem cell transplant with active GVHD, requiring immunosuppressive drugs for treatment of GVHD.
    Have received anticancer therapy, including chemotherapy or radiation therapy, within 14 days before the first dose of the study drug.
    Have received targeted inhibitors within the 5 half-lives of the specific agent before the first dose of the study drug.
    Have received mAb directed to cancer within 28 days before the first dose of study drug.
    Have received corticosteroid more than the equivalent prednisone dose of 60 mg daily for antineoplastic intent within 5 days before the first dose of the study drug, unless it is used to c

Additional Info

The primary objective of this study is to compare the saftey and effectiveness of sonrotoclax plus obinutuzumab versus venetoclax plus rituximab.

For more information search NCT06943872 at www.clinicaltrials.gov

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org